Skip to main
ACET

ACET Stock Forecast & Price Target

ACET Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Adicet Bio Inc. is poised for positive momentum due to the anticipated readouts from its clinical trials, particularly in the treatment of lupus nephritis (LN) and systemic lupus erythematosus (SLE), with management expressing confidence in a favorable outcome. The product candidate, ADI-001, distinguishes itself from traditional autologous CAR-T therapies by demonstrating comparable efficacy while offering a superior safety profile and off-the-shelf scalability, eliminating the need for leukapheresis. These attributes position ADI-001 as a competitive player in the CAR-T therapy market, potentially making it a first-choice treatment option.

Bears say

Adicet Bio Inc is projected to incur a net loss of $1.13 per share in 2025, with various risks including negative clinical data, slower clinical development timelines, and potential regulatory approval setbacks. The company faces challenges with delays in clinical trial initiation and unexpected safety issues, which could hinder the success of its product candidates, such as ADI-001 and ADI-270. Additionally, the reliance on external financing until achieving cash flow positivity poses a long-term dilution risk that could affect shareholders negatively.

ACET has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Adicet Bio, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Adicet Bio, Inc. (ACET) Forecast

Analysts have given ACET a Strong Buy based on their latest research and market trends.

According to 2 analysts, ACET has a Strong Buy consensus rating as of Dec 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Adicet Bio, Inc. (ACET)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.